Tab. 3.
Cytotoxicity of the studied compounds against individual tumor cell lines
| Cpd. | Cancer type | Most sensitive cell lines | pGI50 | pTGI | pLC50 |
|---|---|---|---|---|---|
| IIa | Leukemia | CCRF-CEM | 5.64 | 5.20 | < 4.00 |
| HL-60(TB) | 5.90 | 5.49 | 5.08 | ||
| K-562 | 5.65 | 5.13 | < 4.00 | ||
| MOLT-4 | 5.76 | 5.37 | 4.67 | ||
| RPMI-8226 | 5.74 | 5.28 | < 4.00 | ||
| SR | 5.70 | 5.17 | < 4.00 | ||
| Non-small cell lung cancer | NCI-H322M | 5.92 | < 4.00 | < 4.00 | |
| Colon cancer | COLO 0205 | 5.73 | 5.36 | 4.99 | |
| Melanoma | MALME-3M | 6.10 | 5.30 | < 4.00 | |
| Renal cancer | TK-10 | 5.97 | 4.63 | < 4.00 | |
| Breast cancer | BT-549 | 5.83 | 4.52 | < 4.00 | |
|
| |||||
| IIb | Leukemia | K-562 | 5.59 | < 4.00 | < 4.00 |
| MOLT-4 | 5.56 | < 4.00 | < 4.00 | ||
| CNS cancer | SNB-75 | 5.72 | < 4.00 | < 4.00 | |
| Renal cancer | CAKI-1 | 6.55 | < 4.00 | < 4.00 | |
| Breast cancer | T-47D | 5.63 | < 4.00 | < 4.00 | |